Swiss Red Cross
https://www.redcross.ch/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Swiss Red Cross
Cerenis: Aspiring to Esperion?
When Esperion's ex-VP chemistry and technologies Jean-Louis Dasseux, PhD co-founded Cerenis Therapeutics in March 2005, he was doubtless inspired partly by Esperion's $1.25 billion sale to Pfizer in December 2003. So were a handful of top-notch VCs including Sofinnova Partners and HealthCap (a previous investor in Esperion), who poured in €25 million ($30.5 million) in August 2005.
Going Back to School
Often started by the academic inventors or their laboratory acolytes, biotechs offer equity participations (to universities and researchers) as well as focused attention to their inventions. As large companies have steadily invested in and improved their own discovery operations, in particular going further into the basic research which is the stuff of academic labs, they find themselves positioned to exploit university research in a more focused way-and thus are more willing than ever to do universi
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice